CTOs on the Move

Blade Therapeutics

www.blademed.com

 
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.blademed.com
  • 442 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.278.4291

Executives

Name Title Contact Details

Similar Companies

Affordable RX

Affordable RX is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TrialAssure

TrialAssure – the technology arm of MMS Holdings – is an award-winning, global clinical trial disclosure and transparency reporting suite with unmatched experience in helping clients navigate complex regulatory submission and reporting challenges. TrialAssure helps meet regulatory compliance goals through a flexible, scalable, and streamlined platform that regularly adapts to ever-changing clinical trial disclosure requirements. Established in 2009, the TrialAssure suite was built from the ground up as a single, integrated transparency system, and it is continually strengthened by the experience of leading pharmaceutical industry compliance experts.

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elk Hill

Elk Hill enables children and families to transform overwhelming challenges into successful futures by offering behvioral health and education services.

Macrolide Pharmaceuticals

Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.